| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2015PLoSO..1033595V |
| P356 | DOI | 10.1371/JOURNAL.PONE.0133595 |
| P932 | PMC publication ID | 4514760 |
| P698 | PubMed publication ID | 26208356 |
| P5875 | ResearchGate publication ID | 280373059 |
| P50 | author | Juan García-Arriaza | Q79782431 |
| Francisco J Chichón | Q80502604 | ||
| Suresh C Raman | Q114406516 | ||
| César Santiago | Q55189718 | ||
| Carlos Oscar Sanchez Sorzano | Q56027899 | ||
| Aneesh Vijayan | Q56794286 | ||
| José L Carrascosa | Q64019192 | ||
| Mariano Esteban | Q30004051 | ||
| P2093 | author name string | José Javier Conesa | |
| P2860 | cites work | Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120 | Q72067428 |
| Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope | Q80150785 | ||
| Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein | Q80850760 | ||
| Calcium-phosphate-mediated Transfection of Eukaryotic Cells with Plasmid DNAs | Q83833861 | ||
| Structural mechanism of trimeric HIV-1 envelope glycoprotein activation | Q21131394 | ||
| A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses | Q21135240 | ||
| Identification of a major co-receptor for primary isolates of HIV-1 | Q22251282 | ||
| HIV Drug Resistance: Problems and Perspectives | Q26864534 | ||
| Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions | Q27320923 | ||
| Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | Q27644478 | ||
| Structure of the measles virus hemagglutinin bound to the CD46 receptor | Q27658662 | ||
| A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield | Q27675032 | ||
| Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans | Q27678062 | ||
| The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies | Q27680688 | ||
| Core structure of gp41 from the HIV envelope glycoprotein | Q27736064 | ||
| Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia | Q28254584 | ||
| The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus | Q28259668 | ||
| Primer: inflammasomes and interleukin 1beta in inflammatory disorders | Q28263370 | ||
| A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies | Q28299280 | ||
| GP120: target for neutralizing HIV-1 antibodies | Q28303124 | ||
| Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial | Q28305565 | ||
| Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome | Q28389050 | ||
| Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains | Q28537991 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Central memory and effector memory T cell subsets: function, generation, and maintenance | Q29615097 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| IgG2 subclass deficiency: IgG subclass assays and IgG2 concentrations among 8015 blood donors | Q68148638 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| CD8+T-cell-mediated control of HIV-1 and SIV infection | Q30397667 | ||
| HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells | Q33305012 | ||
| Image processing for electron microscopy single-particle analysis using XMIPP. | Q33341061 | ||
| A clustering approach to multireference alignment of single-particle projections in electron microscopy | Q33548939 | ||
| Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens | Q33627613 | ||
| Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins | Q33806056 | ||
| Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination | Q33977866 | ||
| A role for the chemokine RANTES in regulating CD8 T cell responses during chronic viral infection | Q33981265 | ||
| Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia | Q34049077 | ||
| Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates | Q34096530 | ||
| Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein | Q34097650 | ||
| Memory CD8 T-cell differentiation during viral infection | Q34152220 | ||
| Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein | Q34274515 | ||
| An overview of the determinants of CCR5 and CXCR4 co-receptor function | Q34310385 | ||
| The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. | Q34341843 | ||
| Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. | Q34361680 | ||
| Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial | Q34374835 | ||
| Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection | Q34402934 | ||
| In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. | Q34445208 | ||
| Living in a house of cards: re‐evaluating CD8+ T‐cell immune correlates against HIV | Q34514374 | ||
| Effector and memory T-cell differentiation: implications for vaccine development | Q34632071 | ||
| Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways | Q34796206 | ||
| Crystal structure of vaccinia viral A27 protein reveals a novel structure critical for its function and complex formation with A26 protein | Q34976944 | ||
| Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine | Q35009558 | ||
| Vaccines that stimulate T cell immunity to HIV-1: the next step | Q35073079 | ||
| HIV-1-specific antibody responses during acute and chronic HIV-1 infection | Q35096836 | ||
| Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures | Q35105223 | ||
| A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene | Q35110976 | ||
| Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 | Q35192782 | ||
| Effects of adjuvants on IgG subclasses elicited by virus-like particles | Q35848642 | ||
| HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. | Q36132728 | ||
| The development of CD4 binding site antibodies during HIV-1 infection | Q36155396 | ||
| Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study | Q36315197 | ||
| Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape | Q36388754 | ||
| In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. | Q36529013 | ||
| Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. | Q36692987 | ||
| Innate Immune Sensing of HIV-1 by Dendritic Cells | Q36748027 | ||
| Harnessing CD4+ T cell responses in HIV vaccine development | Q36766715 | ||
| Identification of an HIV-1 Clade A Envelope That Exhibits Broad Antigenicity and Neutralization Sensitivity and Elicits Antibodies Targeting Three Distinct Epitopes | Q36827300 | ||
| Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression | Q37356036 | ||
| Human immunodeficiency virus type 1 gp120 induces abnormal maturation and functional alterations of dendritic cells: a novel mechanism for AIDS pathogenesis. | Q37492783 | ||
| Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. | Q37643731 | ||
| A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. | Q37643733 | ||
| Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets | Q37682352 | ||
| Unique features of memory T cells in HIV elite controllers: a systems biology perspective | Q37856675 | ||
| The vaccinia virus 14-kilodalton (A27L) fusion protein forms a triple coiled-coil structure and interacts with the 21-kilodalton (A17L) virus membrane protein through a C-terminal alpha-helix | Q38331459 | ||
| Five Lec1 CHO cell mutants have distinct Mgat1 gene mutations that encode truncated N-acetylglucosaminyltransferase I. | Q38356775 | ||
| Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). | Q38484762 | ||
| The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. | Q38725610 | ||
| Efficiency of Neutralizing Antibodies Targeting the CD4-Binding Site: Influence of Conformational Masking by the V2 Loop in R5-Tropic Clade C Simian-Human Immunodeficiency Virus | Q38961133 | ||
| Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand | Q39358681 | ||
| Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus | Q39596379 | ||
| Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Review article. | Q40765962 | ||
| Human plasmacytoid dendritic cells efficiently capture HIV-1 envelope glycoproteins via CD4 for antigen presentation | Q41829933 | ||
| Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus | Q41876028 | ||
| Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells | Q41915015 | ||
| Priming for high interferon-gamma production induced by interleukin-12 in both CD4+ and CD8+ T cell clones from HIV-infected patients | Q42114649 | ||
| Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines | Q42230293 | ||
| AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection | Q43135807 | ||
| Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine | Q43779185 | ||
| Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120. | Q43926940 | ||
| Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. | Q45235855 | ||
| Structural and functional properties of the 14-kDa envelope protein of vaccinia virus synthesized in Escherichia coli | Q45849766 | ||
| Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates | Q46243551 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccinia virus | Q1986297 |
| virology | Q7215 | ||
| P304 | page(s) | e0133595 | |
| P577 | publication date | 2015-07-24 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen | |
| P478 | volume | 10 |
| Q40290590 | A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8+ T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria |
| Q89633807 | Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B |
| Q38694270 | Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems. |
| Q92188831 | The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1 |
Search more.